Gynekologisk kreft
- Prosjektnummer
- SFP862-09
- Ansvarlig person
- Anne Ørbo
- Institusjon
- Universitetssykehuset Nord-Norge HF
- Prosjektkategori
- Doktorgradsstipend
- Helsekategori
- Cancer and neoplasms
- Forskningsaktivitet
- 5. Treatment Development
Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
BJOG 2016 Aug;123(9):1512-9. Epub 2015 des 2
PMID: 26630538
Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Anticancer Res 2015 Dec;35(12):6401-9.
PMID: 26637849
Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Anticancer Res 2014 May;34(5):2319-24.
PMID: 24778038
Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
BJOG 2014 Mar;121(4):477-86. Epub 2013 nov 28
PMID: 24286192
Increased gene expression of the ABCC5 transporter without distinct changes in the expression of PDE5 in human cervical cancer cells during growth.
Anticancer Res 2012 Aug;32(8):3055-61.
PMID: 22843873
MCF-7 Cell Apoptosis and Cell Cycle Arrest: Non-genomic Effects of Progesterone and Mifepristone (RU-486).
Anticancer Res 2010 Dec;30(12):4835-40.
PMID: 21187460
Prognostic markers for detection of coexistent carcinoma in high-risk endometrial hyperplasia.
Anticancer Res 2010 Nov;30(11):4649-55.
PMID: 21115919
Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
Acta Obstet Gynecol Scand 2010 Nov;89(11):1438-46.
PMID: 20955098
Down-regulation of progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonor
International Gynecologic Cancer Society Praha. 23-26 oct. 2010
Endometriehyperplasi forskning og behandling- erfaring gjennom 10 år
Invitert foredrag 25 november 2010 Oslo Gynekologisk forening, Oslo
Endometriehyperplasi - nye aspekter ved behandling og oppfølgning
Regionmøte for gynekologer, Tromsø, 10.desember 2010
Invited participant of the Mirena European Expert Meeting as leader of two workshops: Mirena and myoma of the uterus
Mirena European Expert Meeting Brussels, Belgium April 21-23, 2010
Early effects of high concentrations of progestins and antiprogestins A gene expression study of Ishikawa cells.
. The Journal of Steroid Biochemistry and Molecular Biology 2009 Jan;113(1-2):139-149. Epub 2008 Dec 24.
"Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa)
Anticancer Res. 29 (4) 1047-1052 (2009).
"High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis"
Res.29 (4), 1053-1058 (2009).
Prognostic markers for coexistent carcinoma in high risk endometrial hyperplasia with negative D-score Significance of morphome
Acta Obstet Gynecol Scand 2009;88(11):1234-42.
- Anne Beate Vereide Prosjektdeltaker
- Anne Ørbo Prosjektleder
- Rita Kral Doktorgradsstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport, Helse Nord